Last Updated: May 26, 2026

Details for New Drug Application (NDA): 219772

✉ Email this page to a colleague

« Back to Dashboard

NDA 219772 describes BRIVARACETAM, which is a drug marketed by Hainan Poly, Micro Labs, MSN, Alkem Labs Ltd, Lupin, Regcon Holdings, Zhejiang Poly Pharm, Apotex, Aurobindo Pharma Ltd, Centaur Pharms Pvt, Lupin Ltd, Sunshine, and Zydus Pharms, and is included in fifteen NDAs. It is available from fourteen suppliers. Additional details are available on the BRIVARACETAM profile page.

The generic ingredient in BRIVARACETAM is brivaracetam. Fifteen suppliers are listed for this compound. Additional details are available on the brivaracetam profile page.

Summary for 219772

Tradename:	BRIVARACETAM
Applicant:	Alkem Labs Ltd
Ingredient:	brivaracetam
Patents:	0

Pharmacology for NDA: 219772

Mechanism of Action	Epoxide Hydrolase Inhibitors

Suppliers and Packaging for NDA: 219772

Tradename	Generic Name	Dosage	NDA	Application Type	Supplier	National Drug Code	Package Code	Package
BRIVARACETAM	brivaracetam	SOLUTION;ORAL	219772	ANDA	Ascend Laboratories, LLC	67877-904	67877-904-58	1 BOTTLE in 1 CARTON (67877-904-58) / 300 mL in 1 BOTTLE

Profile for product number 001

Active Rx/OTC/Discontinued:	RX	Dosage:	SOLUTION;ORAL			Strength	10MG/ML
Approval Date:	Feb 23, 2026	TE:	AA	RLD:	No

Complete Access Available with Subscription

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.